Ayako Tanaka

Pretreatment advanced lung cancer inflammation index (<scp>ALI</scp>) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya et al. · Cancer Medicine · 2017 · 121 citations · Full text

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study

Shintaro Kanda, K. Goto, Hideaki Shiraishi et al. · Annals of Oncology · 2016 · 94 citations · Full text

Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness

Hisashi Takeuchi, Michio Tanaka, Ayako Tanaka et al. · Oncology Letters · 2016 · 77 citations · Full text

Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status

Yoshio Ohno, Jun Nakashima, Makoto Ohori et al. · International Journal of Clinical Oncology · 2013 · 58 citations

Urology, Surgical Oncology, Renal Function +10

Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents

So Takata, Genju Koh, Yuki Han et al. · Journal of Infection and Chemotherapy · 2018 · 55 citations · Full text

Pulmonary Tuberculosis, Cancer Immunosurveillance, Medicine +14